logo
EXCLUSIVE The truth about 'suicide headaches' and the bizarre treatments I tried in search of a cure

EXCLUSIVE The truth about 'suicide headaches' and the bizarre treatments I tried in search of a cure

Daily Mail​20-07-2025
Tom Zeller Jr has done just about anything to get rid of his headaches.
He's chugged 60 glasses of water in a day, inhaled oxygen straight from the tank and even tripped on magic mushrooms on top of the western Montana mountains.
The 56–year–old science journalist was diagnosed about three decades ago with cluster headaches, debilitating headaches that strike randomly and drag out for weeks or months at a time.
While it could be years between attacks, they return as fast as a lightning strike, with Zeller likening them to resting your hand on a hot burner and not being able to take it off.
Zeller told DailyMail.com: 'They're excruciatingly painful. The tend to come on really, really quickly, within a matter of seconds. You don't usually have a warning and they will knock you down to the floor until they're over.'
Zeller, who lives in Montana, spent much of his adult life suffering attacks up to four times a day for months at a time until they suddenly disappeared.
His clusters have slowed in recent years, but like the 1 in 1,000 Americans with the disorder, Zeller waits for the next attack with limited tools at his disposal.
In his newly released book, The Headache: The Science of a Most Confounding Affliction – and a Search for Relief, Zeller detailed his decades–long search for cluster headache relief, along with the wackiest things he's tried to quell the pain.
'I never wanted to write this book, to be honest. I did not want people to know I had headaches. It's just terrible to be seen in this way,' Zeller told DailyMail.com.
'But I also felt like if you're going to write a book, they say, "Write about what you know." I realized that I know headaches.'
Cluster headaches are extremely painful and strike quickly in frequent attacks, or 'clusters,' lasting weeks or months at a time, earning the grim nickname 'suicide headaches.'
The disorder usually causes sharp and stabbing pain in or around the eye, restlessness, tears and eye redness, forehead sweating, swelling around the eye and eyelid drooping.
While a close relative of migraines, they're far less common. About 0.1 percent of Americans have had a cluster headache attack at some point in their lives, while 15 percent – most of whom are women – have migraines.
For Zeller, the attacks drove a wedge in his journalism career, often forcing him to 'retreat from opportunities in the newsroom.'
'It's not easy. The book talks about how any sort of headache disorder is kind of a drag on the momentum of your life. They're always slowing you down,' he said.
'When I wasn't having the headaches, I felt like I was pretty bold and pretty accomplished as a journalist. But when the headaches would come on, I would sort of disappear and I would work from home a lot.
'There's a lot of stigma attached to headaches in a weird way. I tried very hard to make sure that no one knew that I had these headaches. You start to hide and that meant hiding from opportunities at work too.'
Throughout the book, Zeller detailed a laundry list of unorthodox treatments he tried or researched.
'I was being ground down by the relentless injections, self–administered into an abdomen bruised and pockmarked by previous jabs, and overuse of the medication was likely driving an endless cycle of rebound attacks,' he wrote in his book.
'Given this unappealing tableau, why not shrooms?'
Psilocybin, the active compound in magic mushrooms, has been shown to alter how the brain processes and perceives pain signals and is thought to reduce inflammation.
He's also tried inhaling capsaicin, an extract in chili peppers that gives them their signature heat. Some research suggests it helps desensitize nerve fibers in the nasal passages that transmit cluster headache pain to the brain.
Zeller also rented oxygen tanks from a welding supplier as a 'really fast way to abort a cluster headache attack.'
'I also remember a forum saying that if you just tried to chug like 60 glasses of water a day, or some absurd amount, it would cure your headaches. I was willing to try, but all I did was visit the toilet a lot with headaches,' he recalled.
Zeller said many patients with cluster headaches have to rely on bizarre hacks because of the lack of medications geared specifically toward their condition.
'The thing that surprised me most, and what probably prompted the book, was that so little research was out there on primary headache disorders,' Zeller explained.
Patients are often prescribed beta blockers, antipsychotics, antidepressants and other drugs manufactured for other illnesses, as they can treat headaches in some people.
Recently, the advent of CGRP drugs has changed the picture. Approved by the FDA in 2018, these preventative drugs block or reduce the effects of CGRP, which causes migraine and cluster headache pain.
'A lot of times you'll find a drug or remedy that does kind of work, but the body adapts. We're very plastic, and over time, those things start to wane,' Zeller said.
Zeller uses the CGRP medication Emgality, the only FDA approved medication specifically designed for cluster headaches and migraines.
The cluster headache dose of Emgality is significantly higher than the migraine dose – 300 milligrams compared to 120 milligrams – and both versions are given through a subcutaneous injection just under the skin.
'Cluster headaches are their own unique animal, so once the headaches start happening, it does seem to be pretty hard to stop,' Zeller revealed.
'But I think three times in I'm sort of convinced that the CGRP blockers work for me to stop a bout from happening.'
Like migraines, cluster headaches often become less frequent and severe with age, which some research suggests could be due to hormonal fluctuations and altered blood vessel function in the brain.
Zeller's clusters in recent years have slowed and can now fall years apart, but he's far from being in remission.
'I don't think I, or anyone really, is out of the woods yet,' he said.
For now, Zeller said he hopes his new book will help improve cluster headache awareness and provide a sense of community for readers with the condition.
In his research, he spoke with several cluster headache and migraine patients who at first were 'guarded' and wary of speaking about their experience over fears of it being trivialized.
But throughout the interviews, they became excited because they had 'this pent–up desire to just unload about it.'
'I hope they feel seen by the book,' Zeller said.
'Someone out there is paying attention and you can take heart in that, and if you're able to buy time between painful bouts, I hope that you know the book will be affirming in that you know you're not alone.'
The Headache: The Science of a Most Confounding Affliction – and a Search for Relief is available on Amazon, Barnes & Noble, Target and others.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US senators Wyden and Warren launch investigation into UnitedHealth over alleged nursing home payments
US senators Wyden and Warren launch investigation into UnitedHealth over alleged nursing home payments

Reuters

time27 minutes ago

  • Reuters

US senators Wyden and Warren launch investigation into UnitedHealth over alleged nursing home payments

Aug 7 (Reuters) - Senators Ron Wyden and Elizabeth Warren are launching an investigation into UnitedHealth Group (UNH.N), opens new tab related to allegations that the healthcare conglomerate secretly paid nursing homes thousands in bonuses to help slash hospital transfers for ailing residents. In a letter dated August 6 to UnitedHealth CEO Stephen Hemsley, the senators called on the company to provide detailed information about its reported incentive programming and its impact on residents. The senators have sought responses by September 8. In May, the UK's Guardian newspaper reported the company made secret payments to nursing homes, as part of a series of cost-cutting tactics, that saved the company millions, but at times risked residents' health, citing an investigation carried out by the newspaper. At that time, UnitedHealth had said the U.S. Department of Justice had investigated those allegations, interviewed witnesses, and obtained thousands of documents that demonstrated the significant factual inaccuracies in the allegations.

Struggling US healthcare stocks endure rough 2025 but draw some bargain hunters
Struggling US healthcare stocks endure rough 2025 but draw some bargain hunters

Reuters

time27 minutes ago

  • Reuters

Struggling US healthcare stocks endure rough 2025 but draw some bargain hunters

NEW YORK, Aug 7 (Reuters) - Woes for U.S. healthcare stocks have worsened this year driven partly by Trump administration policies, although some investors are betting that the beaten-down shares are now becoming too much of a bargain to pass up. The S&P 500 healthcare sector (.SPXHC), opens new tab -- which includes pharmaceutical companies, biotechs, health insurers and medical equipment makers -- has slumped 5% in 2025, lagging the over 7% gain for the overall index (.SPX), opens new tab. Pressure to bring down U.S. prescription drug prices to overseas rates, tariffs targeted at pharmaceuticals and cuts to areas such as health research funding and Medicaid are among the Trump administration actions clouding the outlook for the shares this year, investors said. Regulatory obstacles are compounding issues, including expiring drug patents and setbacks for bellwethers including UnitedHealth Group (UNH.N), opens new tab. "You have got this constant overarching political and regulatory overhang that doesn't really seem to subside with any administration," said Jared Holz, healthcare sector strategist at Mizuho Securities. "When you have so much nebulousness around the sector, it turns people off rather than invites them to the party." In another sign of the group losing favor, healthcare exchange-traded-funds have seen 12 consecutive months of net outflows as of July for a total outflow of $11.5 billion in that time, more than for any other sector, according to State Street Investment Management. The performance picture is even dimmer over a longer period. While shares of massive technology companies pushed the benchmark S&P 500 up over 50% the past three years, the healthcare sector is little changed in that time. That gap has put the 60-stock sector at nearly its biggest discount to the broader market in 30 years, which some investors hope is an inflection point for the battered group. "The valuation is extremely cheap and the relative performance is at an extreme," said Walter Todd, chief investment officer at Greenwood Capital, whose healthcare holdings include diversified giant Johnson & Johnson (JNJ.N), opens new tab and medical device maker Stryker (SYK.N), opens new tab. "So at this point, it seems like a pretty decent setup to get some outperformance." The price-to-earnings ratio for the healthcare sector, based on earnings estimates for the next year, has fallen to 16.2 times from nearly 20 a year ago, according to LSEG Datastream. Meanwhile, the S&P 500's rally to records has driven the index's P/E ratio to over 22 times -- giving the broader market a significant premium over the healthcare sector. Some high-profile healthcare names are at even cheaper valuations. For example, Merck (MRK.N), opens new tab is trading at a forward P/E of 8.7, against its long-term average of 14.5, while fellow drugmaker Bristol Myers Squibb (BMY.N), opens new tab trades at 7.4 against its average of 15.8, according to LSEG. Year-to-date, shares of both Merck and Bristol Myers are down roughly 20%. The group is drawing bets from some value investors such as Patrick Kaser, portfolio manager at Brandywine Global, whose portfolio is overweight the sector including owning shares of CVS Health (CVS.N), opens new tab and European drugmakers GSK (GSK.L), opens new tab and Sanofi ( opens new tab. "Our perspective is a lot of this bad news is priced in and then some," Kaser said. "To bet against the sector from here, you're essentially continuing to bet on the valuation gap, which is already large, continuing to widen." The group's decline means the total market value of the S&P 500 healthcare sector is about $4.8 trillion, not much higher than the $4.3 trillion value of Nvidia (NVDA.O), opens new tab, the semiconductor company that has symbolized the artificial intelligence boom. Indeed, some investors said a shift in capital away from Nvidia and other massive tech companies could spark healthcare shares. Such a move appeared to occur in the first quarter, investors said, when the healthcare sector rose 6% while declines in tech and megacap stocks dragged indexes lower. Fears of an economic downturn also could help healthcare shares, at least on a relative basis. The group is often viewed as a defensive area in rockier economic times. Economic fears flared following last Friday's weaker-than-expected employment report, while some strategists say the market could be due for a pullback after surging over 20% since its April lows. "During the first quarter, healthcare did great even as tech rolled over, as the fears of an economic slowdown got to more economically sensitive stocks," said Chris Grisanti, chief market strategist at MAI Capital Management, adding he expects healthcare "will perform better in a more difficult market." More clarity on regulatory issues, including tariffs, also could support healthcare, investors said. But some value investors are hesitant to dive into the group. Michael Mullaney, director of global markets research at Boston Partners, said he is wary some healthcare shares could be "value traps," preferring to overweight areas including industrials or financials. "There's been just so much of an overhang in the sector," Mullaney said. "There are better places to go with cleaner stories."

Focus: Trump, pharma industry discuss boosting medicine spending abroad to cut US prices, sources say
Focus: Trump, pharma industry discuss boosting medicine spending abroad to cut US prices, sources say

Reuters

time27 minutes ago

  • Reuters

Focus: Trump, pharma industry discuss boosting medicine spending abroad to cut US prices, sources say

NEW YORK, Aug 7 (Reuters) - The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere in order to cut drug costs in the United States, according to a White House official and three pharmaceutical industry sources. U.S. officials told drug companies it would support their international negotiations with governments if they adopt "most favored nation" pricing under which U.S. drug costs match the lower rates offered to other wealthy countries, the White House official said. The U.S. is currently negotiating bilateral trade deals and setting tariff rates on the sector. The Trump administration has asked some companies for ideas on raising prices abroad, two of the sources said, describing multiple meetings over several months aimed at lowering U.S. prices without triggering cuts to research and development spending drugmakers insist would result. The White House official called the effort collaborative, saying both sides were seeking advice from each other. The U.S. pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. President Donald Trump has repeatedly said he wants to narrow this gap to stop Americans from being "ripped off." The previously unreported discussions reflect the challenges Trump faces to achieve that goal, and are the backdrop to the letters he sent last week to CEOs of 17 major drugmakers, urging them to cut U.S. prices to match those paid overseas. Unlike in the U.S., where market forces determine drug prices, European governments typically negotiate directly with companies to set prices for their national healthcare systems. Anna Kaltenboeck, a health economist at Verdant Research, said European nations have leverage to drive pricing and are sometimes willing to walk away from purchasing medicines they deem too expensive. Drugmakers generate most of their sales in the U.S. The Pharmaceutical Research and Manufacturers of America - the industry's main lobby group - has always argued that cutting U.S. prices would stifle innovation by lowering R&D spending. PhRMA declined to comment on the private meetings. Kaltenboeck said past studies had shown that drugmakers made enough money in the U.S. to more than fund their entire global R&D spends. "Prices can come down in the United States without being increased in other countries, and we can still get innovation," she said. Despite the Trump administration's tariff threats and pressure to move more manufacturing to the U.S., the push to raise European drug prices is its top priority in discussions with industry, according to a senior executive at a European drugmaker, who spoke on condition of anonymity about the confidential meetings. "This is the key conversation right now with PhRMA and every company getting that message from Pennsylvania Avenue to a point that we are already executing on it," the executive said, referring to the White House address. The company had already met with European governments on the issue, the executive added. An E.U. Commission spokesperson said it is in regular contact with the pharma industry and pointed to an agreement with the U.S. that should it impose tariffs on pharmaceuticals, they would be capped at 15%. When asked how the administration would support international drug price negotiations, the White House official referred Reuters to Trump's most favored nation executive order from May. That order directed trade officials to pursue trade and legal action against countries keeping drug prices below fair market value. In last week's letters, Trump complained that since the May executive order, most industry proposals had simply shifted blame for high prices or requested policy changes that would result in billions in industry handouts. A second source, a pharmaceutical executive who was not authorized to speak on the matter, said the Trump administration has been continually meeting with representatives of his company and had discussed strategies for raising drug prices internationally. "There's a big push from the administration to drive up prices outside the U.S.," the executive said. The executive said the Trump administration had been looking at using trade talks with the UK and EU as leverage, and considered pressuring countries to spend a higher percentage of GDP on new medicines or offering tariff breaks in exchange for higher drug spending. It was understood that the UK deal specifically aims to get the country to ramp up investment in branded medicines over time, the executive said. A spokesperson for the UK government said it would continue to work closely with the U.S. and its own pharmaceutical industry to understand the possible impact of any changes to drug pricing, without commenting on the trade talks. In April, over 30 industry CEOs including those from AstraZeneca (AZN.L), opens new tab, Bayer ( opens new tab and Novo Nordisk ( opens new tab signed a letter to European Union President Ursula von der Leyen saying Europe needed to rethink its pricing policies. "It's going to be very difficult for a country that already has the ability to control what it spends to go in the other direction," Kaltenboeck said, "and it doesn't make much sense for them politically."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store